BeyondAirInc . (NASDAQ:XAIR) was the recipient of a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 46,600 shares, a drop of 9.0% from the September 30th total of 51,200 shares. Based on an average daily trading volume, of 11,100 shares, the short-interest ratio is currently 4.2 days. Approximately 0.6% of the shares of the stock are short sold.
A number of research firms have recently commented on XAIR. Oppenheimer started coverage on BeyondAirInc . in a research note on Tuesday, October 22nd. They issued an “outperform” rating and a $9.00 price objective on the stock. Zacks Investment Research cut BeyondAirInc . from a “hold” rating to a “sell” rating in a research note on Saturday, October 19th. Finally, ValuEngine lowered BeyondAirInc . from a “buy” rating to a “hold” rating in a report on Wednesday, October 30th.
NASDAQ:XAIR opened at $4.03 on Friday. BeyondAirInc . has a twelve month low of $3.11 and a twelve month high of $6.25. The firm’s 50-day simple moving average is $4.42. The company has a market cap of $42.99 million, a price-to-earnings ratio of -4.80 and a beta of -0.29.
In other news, CEO Steven A. Lisi bought 10,000 shares of the business’s stock in a transaction on Monday, November 11th. The stock was purchased at an average cost of $4.19 per share, for a total transaction of $41,900.00. Following the completion of the transaction, the chief executive officer now directly owns 581,318 shares of the company’s stock, valued at approximately $2,435,722.42. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Steven A. Lisi bought 12,000 shares of the business’s stock in a transaction on Wednesday, November 13th. The stock was purchased at an average price of $4.09 per share, with a total value of $49,080.00. Following the completion of the transaction, the chief executive officer now directly owns 581,318 shares of the company’s stock, valued at $2,377,590.62. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 24,939 shares of company stock worth $102,925.
About BeyondAirInc .
Beyond Air, Inc, a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory tract infections and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria.
Featured Story: What is the Book Value of a Share?
Receive News & Ratings for BeyondAirInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondAirInc . and related companies with MarketBeat.com's FREE daily email newsletter.